

FITZPATRICK, CELLA, HARPER & SCINTO

1900 K STREET, N.W.
WASHINGTON, D.C. 20006-1110
(202) 530-1010

Facsimile:(202) 530-1055
FACSIMILE COVER SHEET

AX RECEIVED

APR 30 2003

GROUP 1600

TO:	Examiner Michael Borin Group Art Unit 1631 USPTO	
FROM:	John W. Behringer	
RE:	Application No. 09/674,973 Attorney Docket No. 01702.401500	
FAX NO.:	703-305-3014	
DATE:	April 30, 2003	NO. OF PAGES: 3 <small>(including cover page)</small>
TIME:	SENT BY:	
MESSAGE		

OFFICIAL

Attached is a Supplemental Response to Restriction Requirement.

**IF YOU DO NOT RECEIVE ALL THE PAGES
PLEASE CALL 202-530-1010 AS SOON AS POSSIBLE.**

Note: We are transmitting from a Canon Model FAX-L770
(compatible with any Group I, Group II or Group III machine).

THIS FACSIMILE MESSAGE AND ACCOMPANYING DOCUMENTS ARE INTENDED ONLY FOR THE USE OF THE ADDRESSEE INDICATED ABOVE. INFORMATION THAT IS PRIVILEGED OR OTHERWISE CONFIDENTIAL MAY BE CONTAINED THEREIN. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, REVIEW OR USE OF THIS MESSAGE, DOCUMENTS OR INFORMATION CONTAINED THEREIN IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS MESSAGE IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE OR FACSIMILE AND MAIL THE ORIGINAL TO US AT THE ABOVE ADDRESS. THANK YOU.

01702.401500

PATENT APPLICATION#16
BP
4-30-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
GUSTAV GAUDERNACK, ET AL.)	Examiner: M. Borin
Int'l Appln. No.: PCT/NO99/00143)	Group Art Unit: 1631
U.S. Appln. No.: 09/674,973)	
Nat'l Entry Date: November 8, 2000)	
For: PEPTIDES)	April 30, 2003

Commissioner for Patents
Washington, D.C. 20231

Supplemental Response to Restriction Requirement (Via Facsimile)

Sir:

In the Office Action dated April 16, 2003, the Examiner indicated that in addition to electing the invention of Group I and the amino acid sequence identified as SEQ ID NO. 17, Applicants must also elect one of the Groups from Groups I.1-I.14, and identify the claims that read on the elected SEQ ID NO. 17.

In response, Applicants hereby elect the invention of Group I.2 (Claim 37). Of the Group I claims, Claims 35, 37, 50 and 51 read on the elected SEQ ID NO. 17.

In the interest of prosecution quality and economy for both the Office and Applicants, Applicants again request that the restriction requirement be withdrawn. If the Examiner declines to withdraw the restriction requirement in its entirety, for the reasons